Durability of response to icotrokinra in adults?with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials.

已完结 10 由大三发布于 2026/11/1 19:56:06

DOI:10.1093/bjd/ljag264
作者：Linda Stein Gold,?April W Armstrong,?Jennifer Soung,?Ronald B Vender,?álvaro González Cantero,?Matthias Hoffmann,?Scott T Guenthner,?H Chih-Ho Hong,?Dedee F Murrell,?Eingun James Song,?Leon Kircik,?
文献类型：期刊论文
补充材料：只需要正文

Oxford University Press

Abstract：Background: Icotrokinra, a targeted oral peptide, precisely blocks the interleukin-23 receptor. In two phase III moderate-to--severe plaque psoriasis trials, ICONIC-ADVANCE 1 (NCT06143878) a

应助信息

1天前

Book学术机器人

5e16f875d2aa11f1886c208810ba6e4f.pdf 已采纳

1天前

Book学术机器人

2026/11/1 19:56:06 Book学术AI机器人已找到文献并上传

2026/11/1 19:56:06 Book学术AI机器人收到请求，开始寻找文献

2026/11/1 19:56:06 已向机器人发送请求

1天前

大三发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Multibump Solutions for Critical Choquard Equation